Dr Michael May is President and CEO of CCRM, a Canadian public-private consortium that develops technologies, launches new companies and catalyses investment in regenerative medicine, including cell and gene therapy. Before CCRM, Michael was the President, and co-founder, of Rimon Therapeutics Ltd., a Toronto-based tissue engineering company developing novel medical polymers that possess drug-like activity. In addition, Michael sits on several boards and advisory committees, including the ARM Foundation for Cell & Gene Medicine; AgeX Corporation; panCELLa Inc.; CCRM Enterprises; the International Advisory Board of the Swedish Centre for Advanced Medical Products (CAMP); the Poietis SAB; the Entrepreneurship Leadership Council at the University of Toronto; the Cell and Gene Therapy Insights Editorial Advisory Board; the Commercialization Committee of the International Society for Cell and Gene Therapy and he is the Chairman of ExCellThera Ltd.

Michael Israels is the Chief Financial Officer of the Centre for Commercialization of Regenerative Medicine (CCRM), its for-profit venture arm, CCRM Enterprises Inc., holding company, CCRM Enterprises Holdings Ltd and OmniaBio Inc. Prior to joining CCRM, Michael was a Management Consultant advising asset management firms including institutional investors, pension funds, and retail investment firms, and Professional Accountant at Ernst & Young LLP in Canada, U.K. and Barbados;  President of BEST Funds, a Toronto-based venture capital firm raising funds from retail investors, investing in early-stage companies, and reporting to securities regulators; and CEO of Convexus Managed Services Inc., a start-up investment fund administration company for retail investment funds. Michael is a Chartered Professional Accountant (CPA) and Chartered Accountant (CA, Ontario), a Chartered Business Valuator (CBV), and a graduate of the Ivey Business School at Western University.

Silvio Tiziani is Chief Executive Officer of CCRM Australia and the Director, External Strategy and Engagement of the Australian Regenerative Medicine Institute (ARMI). Silvio has extensive experience in private and public organizations, focusing on laboratory-based organizations in the educational, health and hospital systems. A graduate of the Australian Institute of Company Directors (GAICD), Silvio has a scientific background and qualifications with extensive experience in financial analysis and budget management, business development and strategic planning.